ReviewBioprocess and biosystems engineering2026
Is faster always better? A critical assessment of Vibrio natriegens as microbial host for recombinant protein production.
Review in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marine bacterium Vibrio natriegens has emerged as a promising candidate for recombinant protein production, primarily due to its rapid growth rate combined with its high protein synthesis capacity. These attributes have the potential to shorten production processes while achieving high yields of heterologously produced proteins. This review provides a concise overview of the substantial progress that has been made in the development of genetic tools and expression systems for V. natriegens, highlighting their successful application to the production of a wide range of proteins, including challenging targets such as membrane proteins. In addition, it critically examines the advantages and limitations of this organism as a production host, with a particular focus on whether its rapid growth translates into a tangible benefit for recombinant protein production. By contrasting the current status of V. natriegens with established Escherichia coli-based systems, key technological and biological developments required for its broader adoption are identified. In particular, the scale-up of protein production for potential industrial implementation remains underexplored and may present significant challenges due to the physiological demands of V. natriegens, including high oxygen requirements and the need for salt-supplemented media. Ultimately, whether fast growth equates to superior productivity, and whether V. natriegens can establish itself as a robust and broadly applicable protein production host, will depend on continued strain development and process intensification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.